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Abstract
Background and purpose: Targeted drugs have augmented the cancer treatment armamentarium. Based on the
molecular specificity, it was initially believed that these drugs had significantly less side effects. However, currently
it is accepted that all of these agents have their specific side effects. Based on the given multimodal approach,
special emphasis has to be placed on putative interactions of conventional cytostatic drugs, targeted agents and
other modalities. The interaction of targeted drugs with radiation harbours special risks, since the awareness for
interactions and even synergistic toxicities is lacking. At present, only limited is data available regarding
combinations of targeted drugs and radiotherapy. This review gives an overview on the current knowledge on
such combined treatments.
Materials and methods: Using the following MESH headings and combinations of these terms pubmed database
was searched: Radiotherapy AND cetuximab/trastuzumab/panitumumab/nimotuzumab, bevacizumab, sunitinib/
sorafenib/lapatinib/gefitinib/erlotinib/sirolimus, thalidomide/lenalidomide as well as erythropoietin. For citation
crosscheck the ISI web of science database was used employing the same search terms.
Results: Several classes of targeted substances may be distinguished: Small molecules including kinase inhibitors
and specific inhibitors, antibodies, and anti-angiogenic agents. Combination of these agents with radiotherapy may
lead to specific toxicities or negatively influence the efficacy of RT. Though there is only little information on the
interaction of molecular targeted radiation and radiotherapy in clinical settings, several critical incidents are
reported.
Conclusions: The addition of molecular targeted drugs to conventional radiotherapy outside of approved
regimens or clinical trials warrants a careful consideration especially when used in conjunction in hypo-fractionated
regimens. Clinical trials are urgently needed in order to address the open question in regard to efficacy, early and
late toxicity.
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Background and purpose
Several new anti-cancer drugs have recently entered
clinical practice in oncology. Among those, especially
targeted drugs are promising therapeutic candidates
with a comparatively low toxicity profile. At present,
these drugs are often applied in palliative treatment
situations for metastasized diseases. In addition, targeted
agents are a substantial part of many multimodal onco-
logic treatment schedules. Thus the risk of parallel use
of both radiotherapy and targeted drug is given. With
few exceptions, the toxicity of any combination of
targeted drugs with radiotherapy has not yet been stu-
died in detail.
Key cellular signalling pathways [1] are responsible for
the response of normal tissue and tumour cells to radia-
tion therapy [2]. Although some of the anti-cancer tar-
gets are specific for neoplastic signalling, there is
considerable overlap between neoplastic signalling and
normal cellular signalling. In this regard, several putative
interactions with radiation triggered signalling in normal
issues exist and thus [3,4] influences of targeted drugs
on normal tissue reactions cannot be excluded [5-7].
T h ep r e s e n ta r t i c l er e v i e w st h ee x i s t i n gd a t ao nt h e
toxicity profile and efficacy (if available) of targeted
drugs when applied concurrently to radiotherapy.
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Using the following MESH headings and combinations
of these terms, pubmed database was searched for ran-
domized, prospective and retrospective trials as well as
case reports (all sample sizes were considered):
1. Radiotherapy AND cetuximab/trastuzumab/pani-
tumumab/nimotuzumab
2. Radiotherapy AND bevacizumab
3. Radiotherapy AND sunitinib/sorafenib/lapatinib/
gefitinib/erlotinib/sirolimus
4. Radiotherapy AND thalidomide/lenalidomide.
5. Radiotherapy AND erythropoietin
For citation crosscheck, the ISI web of science data-
base was used employing the same search terms. A
focus was put on prospective or phase I/II trials; if avail-
able, some smaller case studies or case reports were
included if higher toxicities were reported.
In general, grade III + IV toxicities are reported. For
cetuximab, focus was set on larger phase III trials and
those reporting trials specifically reporting toxicities. In
addition, key reviews focusing on the use of targeted
drug in oncology were screened in order to identify
clinically relevant drugs [8].
Results
Antibodies
Cetuximab
Cetuximab is a monoclonal chimeric antibody directed
against the epidermal growth-factor receptor (EGF-R). It
has first been approved for treatment of locally
advanced or metastatic colorectal cancer (k-ras wildtype)
refractory to irinotecan [9]. Regarding radiotherapy, it
has been approved for head-and-neck cancer as an alter-
native to concomitant chemotherapy [10]; in the given
phase III trial overall survival of patients who were trea-
ted by radiotherapy and cetuximab was improved com-
pared to patients who underwent radiotherapy alone.
Cetuximab also has a proven efficacy in locally advanced
or metastatic head-and-neck cancer in combination with
5-FU/cisplatin [11].
Thus several pre-clinical and clinical studies have
provided evidence for the efficacy of cetuximab in
combination with radiotherapy [12-17]. Nevertheless,
several reports are available pointing to increased skin
toxicity after combining cetuximab with radiotherapy
[18-27] (a complete overview is given in Table 1). The
initial publication on the combined use by Bonner and
colleagues reported an increased incidence of an acnei-
form rash [10]. However, in single cases more severe
complications occurred [19]. A recent retrospective
matched-pair evaluation of acute toxicity during cis-
platinum-based radio-chemotherapy versus radiother-
apy with simultaneous cetuximab treatment showed
significantly higher grade 3 oral mucositis and dermati-
t i sa sw e l la sah i g h e rr i s ko fw e i g h tl o s s( >1 0 % )a n d
of enteral feeding requirement in the cetuximab-group.
H o w e v e r ,t h i sm a yb eo u t w e i g h e db yt h eh i g h e rr i s ko f
haematological toxicity by radio-chemotherapy. In
keeping with this, higher compliance rate with less
treatment interruptions in the cetuximab-treated group
was described [26]. In trials on thoracic [28,29] or pel-
vic radiotherapy with cetuximab increased rates of skin
toxicity were not observed.
No other risks regarding additional or increased side
effects concerning connective tissue, CNS [30-32] or
peripheral nerves have been described so far in small
early-phase clinical trials.
Panitumumab
Similar to cetuximab, panitumumab is a monoclonal
antibody directed against EGF-R with a putatively higher
affinity and less toxicity due to its non-chimeric design.
It has been approved for stage IV colorectal cancer
refractory to FOLFOX or FOLFIRI [33].
Only data from a single phase I study [34] and a single
phase II trial described effects of a combination of pani-
tumumab with a 5-FU/oxaliplatin-containing radio-che-
motherapy for rectal cancer [35]. Pre-clinical data
suggest a comparable efficacy to cetuximab [36]. Con-
cerning toxicity, no additional toxicity was observed
when combined with radiotherapy. The phase II trial
reported one toxic death from diarrhea and a relatively
high rate of grade III/IV diarrhea (39%) compared to
the classical CAO/ARO/AIO-94 trial [37]. However,
based on the design of the trial it is not possible to pre-
cisely attribute the side effects to any of the components
of the given protocol.
Nimotuzumab
Nimotuzumab is another humanized therapeutic mono-
clonal antibody directed against EGF-R not yet been
approved by the authorities in Europe. There are three
small phase I trials testing radiotherapy and nimotuzu-
mab in head-and-neck cancer as well as NSCLC
patients; an increased rate of skin toxicity was observed
[38-40]. The other larger phase II trial by Rodríguez and
colleagues was prospectively randomized and 106 head-
and-neck cancer patients were included [38]. No grade
III or IV toxicity has been observed.
The data available suggest that the combination of
cetuximab with radiation may lead to an increased rate
of mucosal- and skin toxicity when applied together
with radiation for the treatment of head-and-neck can-
cer. No such problems have been reported in other
organ regions. It is unclear in how far this is an epitope-
specific side effect-only limited data are available
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Substance Author(s) Year Study type N Tumour RT dose/ChTx/
technique
Toxicity
Cetuximab Bonner et al.
[10]
2006 Phase III 211
(cetux-
arm)
LA-HNSCC 70-78.8 Gy (hyper-
fractionated)
Significant differences or trend in arms: 8%
grade III-V acneiform rash, 1% grade III-V
voice alteration, 1% grade III-V infusion
reaction
Koutcher et al.
[24]
2009 Retrospective 115 LA-HNSCC 66 Gy/69.96 Gy 3% grade IV radio-dermatitis, 19% grade III
radio-dermatitis
Studer et al.
[25]
2011 Prospective 99 HNSCC 66-70 Gy, 30/99
switch from Cis
34% grade II/IV dermatitis
Hallqvist et al.
[28]
2010 Phase II 75 NSCLC 68 Gy, Ind. ChTx
Doc/Cis +
concomitant Cetux
1% grade V pneumonitis, 4% grade III
pneumonitis, 5% grade III + IV
hypersensitivity, 15% grade III + IV febrile
neutropenia, 4% III skin reactions
Jensen et al.
[122]
2010 Retrospective 73 HNSCC 22 pts Re-RT (50-60
Gy), 66-70 Gy
5% grade III allergic reaction, 4% grade III
acneiform rash
Garcia-
Huttenlocher et
al. [123]
2009 Retrospective 65 HNSCC Median 66 Gy (IMRT) Grade III: skin toxicity 28%, mucositis 25%
Rödel et al.
[115]
2008 Phase I/II 12/48 Rectal
cancer
50,4 Gy
+Capecitabine +
Oxaliplatin
Phase II only Grade IV/V: Leukopenia,
thrombocytopenia, Diarrhea, Creatinine
elevation, e-lyte derivation, infection each
2%
Safran et al. [31] 2008 Phase II 60 Esophago-
gastric-
cancer
Cetux/Carbo/Tax +
50.4 Gy
23% grade III rash, 15% grade III/IV
esophagitis, 5% III + IV hypersensitivity, 3%
grade IV neutropenia (10% grade III), 2% IV
anemia (8% grade III)
Jatoi et al. [124] 2010 Phase II 57 NSCLC 60 Gy 2% grade IV each: dysphagia/
hypomagnesemia/dyspnea/headache/
thrombosis/GI hemorrhage, 7% grade III
rash
Horisberger et
al. [30]
2009 Phase II 50 Rectal
cancer
50,4 Gy +
Capecitabine +
Irinotecan
Leukopenia 4% grade III and IV each
Grade III: Diarrhea 60%, abdominal pain
8%, ALAT/ASAT elevation 20%, Acneiform
skin rash 12%, anemia, nausea/vomiting,
bilirubin elevation, proctitis each 4%
Koutcher et al.
[125]
2011 Retrospective 49 LA-HNSCC 69.96 Gy (IMRT)
(comparison vs.
concomitant Cis)
20% late grade III + IV toxicity
Walsh et al. [26] 2011 Retrospective 48 (14
excluded
because
of SIB)
HNSCC Cis vs. Cetux (66-70
Gy)
44% ≥ grade III skin toxicity, 52% ≥ grade
III mucositis, 6% ≥ grade III acneiform rash
Buiret et al.
[126]
2010 Retrospective
multicenter
46 HNSCC Ind. ChTx Doc/Cis/5-
FU, RIT (70 Gy)
No grade IV toxicity
Garcia-
Huttenlocher et
al. [127]
2008 Retrospective 46 HNSCC Median 66 Gy (IMRT) 20% grade III skin toxicity, 4% grade III
mucositis
Merlano et al.
[128]
2010 Phase II 45 HNSCC Up to 70 Gy, three
cycles Cis/5-FU, split
course RT, RT +
cetux
2% grade IV leukopenia (38% grade III), 7%
grade IV neutropenia (33% grade III), 2%
grade IV thrombopenia (13% grade III),
36% grade IV stomatitis (29% grade III),
73% grade III radiodermatitis, 7% grade III
rash
Koukourakis et
al. [60]
2010 Phase I 43 LA-HNSCC 21 × 2.7 Gy (56.7 Gy)
+ amifostine + Cis
16% grade III + IV mucositis, 2% grade III +
IV skin toxicity
Suntharalingam
et al. [129]
2011 Phase II 43 LA-HNSCC 70,2 Gy (3D/IMRT) +
Paclitaxel,
Carboplatin,
Grade 3 mucositis (79%), rash (9%),
leukopenia (19%), neutropenia (19%), and
RT dermatitis (16%)
De Vita et al.
[130]
2011 Phase II 41 Esophageal
cancer
Ind. FOLFOX4 + 50.4
Gy/Cetux
30% grade II/IV skin toxicity/neutropenia
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Bertolini et al.
[117]
2009 Phase II 40 LA rectal
cancer
50-50.4 Gy + neoadj.
Cetux/Cetux + 5-FU
concomitant
8% grade III/IV skin rash, 8% grade III/IV
hypersensitivity, 13% grade III/IV GI toxicity,
3% grade III/IV febrile neutropenia
Kim et al. [98] 2011 Phase II 40 Rectal
cancer
Capecitabine +
Cetux + Irinotecan +
50.4 Gy
3% grade IV leukopenia, 3% grade III rash
Machiels et al.
[119]
2007 Phase I/II 40 Rectal
cancer
45 Gy +
Capecitabine
3% grade III/IV allergic reaction, 3% grade
III/IV dermatitis
Argiris et al.
[131]
2010 Prospective 39 LA-HNC Induction Docetaxel/
Cis/Cetux +
concurrent Cisplatin/
Cetux/70-74 Gy-RT
Grade III/IV: oral mucositis 46%, Anemia
21%, in-field dermatitis 23%, Dysphagia
41%, Thrombocytopenia 10%, Neutropenia
31%, febrile neutropenia 5%, infection
18%, fatigue 13%, nausea 10%, vomiting
3%, renal failure 3%, DVT 5%, bleeding 5%.
Velenik et al.
[118]
2010 Phase II 37 Rectal
cancer
45 Gy RT +
capecitabine
(neoadjuvant)
Grade III: diarrhea 11%, anorexia 3%,
hepatotoxicity 3%, in-field-dermatitis 16%,
infection 3%, hypersensitivity 5%.
Heron et al.
[132]
2011 Matched pair
retrospective
35 HNSCC SBRT Re-RT No significant increase grade III + IV
Birnbaum et al.
[133]
2010 Phase I 32 LA-HNSCC 66-72 Gy, Ind. Cetux
+ Carbo/Tax/Cetux
concomitant
3% grade III allergic reaction, 3% grade IV
metabolic symptom, 69% grade III + IV
mucositis, 3% grade IV dysphagia, 59% pts
grade III + IV skin toxicity
Jensen et al.
[134]
2011 Phase II 30 NSCLC 66 Gy (IMRT) Pulmonary embolism 3% grade III + 3%
grade V endocarditis and myocardial
infarction grade V each 3%, 13% grade III/
IV pneumonia esophagitis, diarrhea, DVT,
exacerbation of COPD, urosepsis,
pericardial effusion, pneumonitis grade III
each 3%
Ruhstaller et al.
[135]
2011 Phase IB/II 28 Esophageal
cancer
Induction ChTx Cis/
docetaxel +
neoadjuvant RCh-
immunotherapy
25% grade III/IV esophagitis, 4% grade III/IV
rash
Pfister et al.
[136]
2006 Phase I 22 LA-HNSCC 70 Gy RT + Cisplatin Study closed due to significant AEs.
Grade V pneumonia and one death of
unknown cause,
Grade IV: MI 5%, arrhythmia 5%, metabolic
5%, infection 5%
Hofheinz et al.
[137]
2006 Phase I 20 Rectal
cancer
Capecitabine +
Irinotecan + 50.4 Gy
No grade IV, no rash, 20% grade III
diarrhea
Kuhnt et al.
[138]
2010 Phase I 18 (16
eligible)
LA-HNSCC HART (70.6 Gy) + Cis 56% grade III mucositis, 38% ≥ grade III
radiodermatitis, 25% ≥ grade III
neutropenia, 6% grade III rash
Pryor et al. [22] 2009 Prospective 13 HNSCC 70 Gy 46% ≥ grade III acneiform rash, 77% ≥
grade III dermatitis
Hughes et al.
[29]
2008 Phase I 12 NSCLC 64 Gy Grade III fatigue, pneumonitis each 8%
Grade V Infection 8%
Zwicker et al.
[139]
2011 Phase II 10 HNSCC IMRT 50.4 Gy Re-RT
+ Cetux
10% grade V mucositis, 10% grade III
mucositis, 10% grade IV erythema (20%
grade III), 20% grade III acneiform rash
Jensen et al.
[140]
2010 prospective 9 Adenoid
cystic
carcinoma
of HN
5/9: re-RT: median
50,4 Gy, median 65
Gy otherwise (IMRT
or C-12 boost)
Grade III Mucositis and Grade III Dysphagia
Balermpas et al.
[141]
2009 Prospective 7 HNSCC Re-irradiation 50,4
Gy-54,0 Gy
New acute side effects:
Grade III: pain 14%, mucositis 71%.
Dysphagia 57%. Xerostomia 14%. Fibrosis
14%, acneiform rash 29%.
Berger et al.
[19]
2008 Case report 1 HNSCC 72 Gy., regimen
change to cetuximab
from 5-FU/MMC
Grade IV Dermatitis
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tumumab and nimotuzumab.
Anti -Her2/neu antibody trastuzumab
Trastuzumab is a humanized monoclonal antibody
directed against the epidermal growth-factor-receptor
Her-2/neu. It is approved for the treatment of metastatic
her-2/neu-positive breast cancer as well as for the adju-
vant treatment of her-2/neu-positive breast cancer in
combination with chemotherapy [41-44].
Cardiac toxicity is a rare, but well described adverse
effect of trastuzumab-especially with or after the treat-
ment with anthracyclins [45-47]. As cardiac toxicity is
also of concern in thoracic radiotherapy, the question of
an increased toxicity has been raised. The largest trial
focusing on side effects of the combined use of radio-
therapy and trastuzumab is the phase III NLCCTG trial
N9831 for adjuvant trastuzumab and radiotherapy
including 1503 patients [48]. The trial did not reveal any
significant differences in toxicity regarding skin, pneu-
monitis or cardiac events. Also, a French multicentric
study [49] including 146 patients did not observe an
increased cardiac toxicity. Another study retrospectively
investigated the combinational approach of trastuzumab
and radiotherapy including the internal mammary
lymph nodes [50]. Again, no increased cardiac toxicity
has been observed.
Thus, at present there are no strong indicators for an
increased cardiac toxicity. However, follow-up periods
are only sufficient for an estimation of early cardiac
toxicity caused by trastuzumab, but not for an in-depth
assessment of late radiation-induced cardiac effects.
Altogether, the current data suggest that the use of
trastuzumab in a close time frame with radiotherapy
may be safe. However, the reported studies might still
reveal an increased cardiac toxicity, as minor vascular
changes might lead to an increased mortality in long-
term follow-up [51].
Table 1 Studies on monoclonal EGFR antibodies (Continued)
Trastuzumab Halyard et al.
[48]
2009 Phase III 1503 Breast
cancer
Median 50,4 Gy,
previous OP + ChTx
Skin toxicity grade III: 4% (simultaneous)
-6% (adjuvant), cardiac events 2%
(simultaneous)-3% (adjuvant)
Belkacemi et al.
[49]
2008 Multicentric
study
146 Breast
cancer
Median 50 Gy > grade II esophagitis (12%), 1 pt grade III
esophagitis, 5% grade III dermatitis, ≥
grade II LVEF (10%)
Caussa et al.
[142]
2011 Prospective 106 Breast
cancer
50 Gy (2 Gy) + 16 Gy
boost
2% grade III skin reaction, 1% grade III
esophagitis
Anderson [143] 2009 Matched case
control study
85 Breast
cancer
n. r. Grade III dermatotoxicity 2%, 1% ≥ grade II
LVEF decrease (reversible)
Shaffer et al.
[50]
2009 retrospective 44 Breast
cancer
40-50.4 Gy In 14% stopped because of cardiac toxicity
Chargari et al.
[144]
2011 Phase I 31 Brain mets
breast
cancer
30 Gy (3 Gy) WBRT No grade > II
Horton et al.
[145]
2010 Phase II 12 Locally
recurrent
breast
cancer
50 Gy, ChTx
refractory
17% grade III skin toxicity, 8% grade III
lymphopenia, no cardiac toxicity
Panitumumab Pinto et al. [35] 2011 Phase II 60 Rectal
cancer
5-fluorouracil-
oxaliplatin + RT
Grade 3-4 toxicity: diarrhea (39%, one toxic
death), cutaneous reactions (19%), nausea,
neutropenia (2%), others.
Wirth et al. [34] 2010 Phase I 19 LA-HNSCC 70 Gy + Carbo/Tax
(2 Gy) IMRT
1 pt grade III febrile neutropenia, 84%
grade III + IV mucositis, 95% grade III
dysphagia, 42% grade III dermatitis, 11%
grade III rash, 21% grade III nausea
Nimotuzumab
(h-R3)
Rodriguez et al.
[38]
2010 Prospective
randomized
106 HNSCC n. r. III/IV not reported
Crombet et al.
[146]
2004 Phase I 24 HNSCC 66 Gy (2 Gy) 4% grade III somnolence, 13% grade III
dysphagia, 21% grade III mucositis, 13%
grade III dermatitis, 4% grade III laryngitis
Bebb et al. [39] 2011 Phase I 18 NSCLC 36/30 Gy (3 Gy) 50% grade III + IV
Choi et al. [40] 2010 Phase I 15 NSCLC 36/30 Gy (3 Gy) 7% grade IV febrile neutropenia/
pneumonia, 40% grade III lymphopenia
N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, HCC-hepatocellular carcinoma, RCC-renal cell cancer, GBM-glioblastoma multiforme,
DVT-deep vein thrombosis, Fx-fractions, SRS-stereotactic radiosurgery, DLT-dose limiting toxicity, LA-locally advanced, Gem-gemcitabine, Tax-Taxol (paclitaxel), Tx-
therapy, TMZ-temozolomide, PCP-Pneumocystis pneumonia, Cis-cisplatin, Eto-etoposide, Doc-docetaxel
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Bevacizumab is a humanized monoclonal antibody
against the vascular endothelial growth-factor (VEGF).
So far, bevacizumab has been approved for the treat-
ment of metastatic colorectal carcinoma, in combination
with standard chemotherapy (5-FU, irinotecan, oxalipla-
tin or capecitabine). Bevacizumab has been approved for
the treatment of metastatic non-squamous-cell bronchial
carcinoma, for the treatment of renal cell cancer and for
the treatment of glioblastoma multiforme (US only).
The FDA has withdrawn the approval for first line treat-
ment of metastatic HER-2/neu-negative breast cancer-
however, the drug still is approved in Europe.
The most common side effects of bevacizumab alone
include impaired wound healing, hypertension, bleeding
problems as well as an increased risk of thromboembolic
events.
One of the first publications to describe an increased
risk of combining bevacizumab with radiotherapy
reported on patients with ischemic bowel complications
after the administration of radiotherapy followed by bev-
acizumab [52].
A phase II study combining neoadjuvant bevacizumab,
capecitabine and radiotherapy for locally advanced rectal
cancer revealed an increased rate of wound complica-
tions such as delayed healing and wound dehiscence
[53]. The data are in line with a number of similar
reports and case studies, supporting the interpretation
that the combined use of bevacizumab with neoadjuvant
radiotherapy is associated with an increased risk of post-
operative complications [54-57]. However, this interpre-
tation is not homogenously supported by all available
data [58-61]. In terms of tumour response, the rate of
pathological complete responses seems to be enhanced
[53].
The use of bevacizumab, capecitabine and radiother-
apy in patients with locally advanced pancreatic cancer
was associated with an increased rate GI-bleeding and
ulcerations (12%) [62]. These complications preferen-
tially occurred in patients with a mucosal infiltration of
the tumour. In a consecutive study -after excluding
patients with mucosa infiltration-no such side effects
were reported [63]. A similar study reported the combi-
nation of radiotherapy with bevacizumab-partly in a
neoadjuvant setting- as “feasible” [64].
The combination of radiotherapy with simultaneous
administration of bevacizumab was also tested for lung
cancer [65,66]. In this setting, the occurrence of severe
fistula leading to a discontinuation of both trials has
been described [66].
In case of breast cancer the parallel combination of
radiotherapy and bevacizumab had no significant side-
effects in regard to lung and skin toxicity [65].
The treatment of malignant tumours of the brain has
been subject to a variety of studies combining radiother-
apy with bevacizumab with or without temozolomide;
regarding progression-free survival, these trials suggest a
benefit of the combined use [67]. No intra-cerebral
bleeding has been reported, however cases of wound
dehiscence of the previous operation have been docu-
mented [68-70]. A collection of case reports points
towards increased late toxicity such as optic neuropathy
and a single case of Brown-Séquard syndrome after a
combination of bevacizumab with radiotherapy [71]. (a
complete overview is given in Table 2).
Altogether, the combined use of bevacizumab and
radiotherapy seems to be associated with a considerable
risk of side effects (wound dehiscence, bleeding, fistula
or GI complications). However, in selected cases the
combination was feasible and even favourable concern-
ing overall survival (retrospective) [69] and progression-
free survival [72].
Anti CD20 monoclonal antibody-rituximab
Rituximab is a monoclonal antibody directed against the
CD20 antigen. It was initially developed and approved
as a targeted agent for the treatment of CD20-positive
non-Hodgkin lymphoma. In this setting, rituximab is
mostly used in combination with chemotherapy (e. g.
CHOP). Apart from the use of rituximab in oncology,
its use has been extended to the treatment of refractory
autoimmune diseases (e. g. rheumatoid arthritis, multi-
ple sclerosis, systemic lupus erythematosus and idio-
pathic thrombocytopenic purpura among others).
The application of rituximab in combination with or
shortly before/after radiotherapy of non-Hodgkin lym-
phoma has been prospectively studied [73-75]. So far no
significant additional toxicities have been reported. All
side effects seen in the trials have been attributed to the
individual therapeutic modalities respectively [76]. Thus,
at present the combination of rituximab with radiation
does not seem to harbour any relevant risks.
Small molecules/tyrosine-kinase inhibitors (TKI’s)
TKI’s are small molecules able to pass the cell mem-
brane and to inhibit intracellular tyrosine kinases of sev-
eral growth factor receptors. Relevant examples are
sunitinib, sorafenib, erlotinib or gefitinib. At present,
TKI are used for diverse cancer entities and various
clinical settings. Key indications are: Metastasized lung
cancer/renal cell cancer/pancreatic cancer, locally
advanced and metastatic breast cancer as well as hepato-
cellular carcinoma.
Up to now, no TKI has been approved for the simul-
taneous use with radiotherapy.
All toxicity data on combined toxicity are limited to
case reports or studies with small numbers of patients.
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Substance Author(s) Year Study type N tumour RT dose/ChTx/
technique
Toxicity
Bevacizumab Vredenburgh
et al. [147]
2010 125 Glioblastoma 59,4 Gy/Temozolomide Grade III Thromboembolic events: 2%
Crane et al.
[63]
2009 Phase II 82 Pancreatic
Cancer
50,4 Gy/Capecitabine Toxicities possibly attributable to bevacizumab: GI
bleeding: 6%. (d83,127,179, 180, 316); grade III, IV, V
GI perforation: 4%. (d195,231,286)
DVT grade III + IV: 4%; grade III hypertension: 2%;
Lai et al. [72] 2010 Phase II 70 Glioblastoma 60 Gy/Temozolomide Grade IV cerebrovascular ischemia: 9%; Grade III+IV
CNS hemorrhage: 3%; Grade III+IV GI bleeding/
perforation 6%; grade IIII Optic neuropathy: 1%.
Grade III+IV venous Thrombosis/PE: 19%.
Crane et al.
[62]
2006 Phase I 48 Pancreatic
Cancer
50,4 Gy/Capecitabine Toxicities possibly attributable to bevacizumab:
grade III+V ulceration with bleeding in RT field: 8%.
(retrospectively fistulous connection identified in
4%)
Grade III GI perforation: 4%; bleeding outside field):
4%; grade III hypertension: 2%.
Seiwert et al.
[148]
2008 Phase I 43 Head & Neck 63-72 Gy/5-FU and
Hydroxyurea
Grade V bleeding events: 5%; grade V infection/
sepsis: 7%, 2% unknown cause of death; grade III+
Thromboembolic events: 5% DVT, 2% stroke
(leading to fatal sepsis, see above); fistula (due to
radionecrosis or residual tumour): 12%. Tissue
necrosis 9%.
Spigel et al.
[149]
2009 Phase II A
29
B5
SCLC 61,2 Gy/Carboplatin/
Irinotecan (A-limited
stage B-locally
advanced)
A Grade IV+V tracheoesophageal fistula: 7%. Grade
V aerodigestive hemorrhage. B Grade III
tracheoesophageal fistula: 40%. Both studies closed
due to toxicity.
Willet et al.
[58]
2009 Phase II 32 Rectal Cancer 50,4 Gy//5-FU Grade III toxicities: GI abscess 3%, Hypertension 9%,
radiation dermatitis: 6%; wound separation 3%. No
grade IV.
Dipetrillo et
al. [55]
2012 Phase I 26 Rectal Cancer 50,4 Gy/FOLFOX Grade III + IV Diarrhea: 42%; Bleeding (g3): 4%; g3
neuropathy: 4%; Radiation dermatitis G3: 8%;
postoperative wound complications: 35%-the study
was discontinued due to this toxicity.
Crane et al.
[53]
2010 Phase II 25 Rectal Cancer 50,4 Gy/Capecitabine grade III perianal desquamation: 4%; 12% major
surgical complications such as anastomotic
dehiscence (4%), wound dehiscence (8%)
Gutin et al.
[68]
2009 Phase I 25 Glioblastoma/
Anaplastic
Gliomas
30 Gy/5 × 6 Gy Grade IV Gastrointestinal bleeding: 4%, bowel
perforation: 4%, wound healing complication: 4%.
Grade III CNS hemorrhage: 4%.
Koukourakis
et al. [59]
2009 Phase I/II 22 Rectal Cancer 15 × 3,4 Gy/amifostine,
capecitabine
Fistula: 9%, grade IV skin necrosis 5%.
Niyazi et al.
[69]
2010 Retrospective 20 Recurrent
Glioblastoma
36 Gy Grade IV wound healing complication: 5%. grade III
DVT: 5%.
Koukourakis
et al. [150]
2011 Phase II 19 Rectal cancer 10 × 3, 4 Gy
Amifostine/
Capecitabine
Grade III diarrhea: 11%.
Goyal et al.
[65]
2010 Retrospective 14 Breast cancer 50 Gy + 10 Gy No Grade III/IV toxicity (only acute toxicity
assessed)
Czito et al.
[61]
2007 Phase I 11 Rectal Cancer 50,4 Gy/Oxaliplatin +
Capecitabine
No grade III + toxicities attributable to
bevacizumab: grade III-IV diarrhea: 27%,
Resch et al.
[151]
2011 Phase II 8 Rectal cancer 45 Gy/Capecitabine Discontinued due to tox after 8 Pt., Grade III GI
bleeding: 25%, Grade III diarrhea: 25%
Kelly et al.
[71]
2010 Case reports 3 Glioblastoma Optic neuropathy
Vargo et al.
[152]
2011 Case report 1 Glioblastoma Dural venous thrombosis
N-number of patients
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Page 7 of 19The clinical indications and the most common adverse
effects of clinically used TKI’s are summarized in Table
3.
When using sunitinib or sorafenib alone, mainly diar-
rhea, hypertension, fatigue, hand-foot syndrome, bleed-
ing and hematotoxicity may occur as side effects.
Concerning combined use with radiotherapy, one case
report described a lethal small bowel perforation after
1x 8 Gy in a palliative setting, sorafenib had been
stopped 2 days before and three days after radiothera-
peutic treatment [77]. In another case, a lethal bronchial
fistula occurred after radiation of the mediastinum [78];
as this phenomenon has been observed after sunitinib
alone [79] no definite causality can be deduced. Further-
more, elevated bone-marrow toxicity was observed if
large volumes of bones or liver were radiated; a phase I
study concluded to avoid the combination with sunitinib
when radiating volumes of more than 6 ccm of the liver.
A dose reduction of sunitinib was advised for the fol-
lowing phase II study [80].
In patients with cerebral metastases increased intra-
cerebral bleeding has been reported, this appears to hap-
pen with or without radiotherapy [81].
Concerning the simultaneous use of gefitinib/erlotinib
and radiotherapy one case of fatal diarrhea after com-
bining erlotinib with RT in the abdomen (2x8 Gy, q1w)
has been reported [82]. And again, in patients with cere-
bral metastases increased intracerebral bleeding has
been reported, however, this appears to happen with or
without radiotherapy [83].
As long as no reliable data concerning the safety of
the combination of TKI’s and radiotherapy are available,
such therapies should be used very carefully, especially
if the above reported organs received relevant radiation
doses. So far it is unclear if the increased intracerebral
bleeding rates are induced by the combined treatment
or by the drug alone. However, because of the severity
of this adverse effect, special caution is warranted for
combined treatment schedules. The same applies for
tumours that tend to bleed outside of the brain. Radio-
therapy in the abdomen or the pelvis together with
TKI’s might lead to an increased toxicity, including the
occurrence of ulcera and bleeding.
mTOR inhibitors
According to pre-clinical data, an improvement of
tumour growth by simultaneous administration of tem-
sirolimus with radiotherapy seems possible [84-86].
However, the only study on long-term local tumor con-
trol revealed no beneficial effect regarding the combined
treatment [84]. Preclinical data show an inhibition of
vascular growth when combining everolimus with radia-
tion, however a direct radio-sensitizing effect could not
be consistently shown [85,86]. A recent study [87]
showed evidence for a suppressed dsDNA break repair
by everolimus.
Concerning toxicity, there is one phase I study using
temsirolimus with topotecan in recurrent gynaecological
malignancies [88]. Dose-limiting toxicity of this combi-
nation was myelo-suppression. Although this toxicity
cannot be attributed to temsirolimus, we advise caution
when combining mTOR-inhibitors with concomitant or
sequential radiotherapy, especially if large volumes of
bone are in-field as the latter is already known to poten-
tially cause myelo-suppression.
Nevertheless there are no sufficient clinical data to
adequately judge the risks and potential benefits of a
combined use of mTOR-inhibitors with radiotherapy. As
long as this is the case, it can be assumed that-similar to
anti-angiogenic substances-the combinational use may
lead to wound healing deficits, increased bleeding and
thrombosis.
Lenalidomide/thalidomide
Data on available studies combining radiotherapy and
lenalidomide or thalidomide treatment are shown in
Table 4. Thalidomide was initially used and approved as
sedative drug until the early 1960s when it became clear
that the intake of “Contergan” during pregnancy could
lead to severe deformities. It was only in the late 1990s
that thalidomide was rediscovered for its anti-angiogenic
properties in cancer therapy [89]. Thalidomide is clini-
cally used in the treatment of multiple myeloma; other
areas of possible clinical use and ongoing clinical trials
include leprosy, erythema nodosum leprosum and mye-
lodysplastic syndrome.
The most common side effects of thalidomide-besides
somnolence-are thromboembolic events as well as per-
ipheral polyneuropathy.
In vitro studies with cells of squamous cell carcinoma
and of multiple myeloma showed no evidence for any
radio-sensitizing quality of thalidomide. However, a
radio-sensitizing effect has been observed in normal
hematopoietic bone marrow [90]. Experiments in mice
showed thalidomide induced tumour re-oxygenation
pointing to a possible radio-sensitizing effect in vivo
[91]. Experiments in rats indicate that thalidomide
might be protective against radiation-induced proctitis
when given 7 days after a single-RT [92].
In humans, thalidomide has been tested in combina-
tion with radiotherapy in phase I-III studies. Most data
exist for radiation of the CNS combined with the
administration of thalidomide.
The largest study so far was conducted by Knisely and
co-workers [93]. In this phase III study 183 patients
with multiple cerebral metastases were randomized for
palliative WBRT (37,5 Gy in 15 fx) vs. WBRT (same
Niyazi et al. Radiation Oncology 2011, 6:177
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Substance Author(s) Year Study type N tumour RT dose/ChTx/technique Toxicity
Sunitinib Chi et al.
[153]
2010 Phase II 23 HCC 52.5 (15 Fx) IMRT/3D-CT 9% grade III upper GI bleeding, 4% hepatitis
grade III/4% grade III pancreatitis, 26% grade
III + IV thrombopenia, 4% grade III leukopenia
Stähler et al.
[154]
2010 Prospective,
non-
randomized
22 RCC (all sites) Median 40 Gy (median 8
Fx)
5% grade IV hypertension, 14% grade III + IV
nausea
Kao et al. [80] 2009 Phase I 21 Oligometastases 40-50 Gy (10 Fx) 62% grade III + IV lymphopenia, 19% grade III
neutropenia, 14% grade III + IV thrombopenia,
5% grade III rectal bleeding
Hui et al.
[155]
2010 Phase II 13 Nasopharyngeal
carcinoma
Sunitinib after RT (60-70 Gy)
and multiple Chx
15% fatal hemorrhages, 31% Grade IV
hemorrhages, (among other toxicities)
sorafenib Peters et al.
[77]
2008 Case study 1 RCC 8 Gy single dose Grade V bowel perforation (stopped two days
before, three days later recommenced)
lapatinib Harrington et
al. [156]
2009 Phase I 31 LA-HNSCC 66-70 Gy + CisPt 35% grade III mucositis, 19% grade III
dermatitis, 13% grade III + IV lymphopenia,
6% grade III neutropenia
gefitinib Cohen et al.
[157]
2010 Phase I 69 LA-HNSCC IC Carbo/Tax, hydroxyurea
+ 5-FU, 2 × 1.5 Gy/d
29% grade III + IV neutropenia, 86% grade III
+ IV mucositis, 33% grade III + IV dermatitis,
3% grade V infections, 17% grade III + IV
infections, 4% grade III rash, 3% grade III
neurotoxicity
Pollack et al.
[158]
2011 Phase II 43 Brainstem
glioma in
children
55,8 Gy Grade III+IV: lymphopenia (21%), neutropenia
(2%), GI (12%), infection (7%), n, pulmonary
(5%), renal, skin (2%), metabolic (2%),
intratumoral hemorrhage: 7%.
Valentini et
al. [159]
2008 Phase I/II 41 Rectal cancer 45 Gy + 5.4 Gy + 5-FU 20% grade III + IV GI toxicity, 15% grade III +
IV skin toxicity, 39% grade III + IV hepatic
toxicity, 10% grade III + IV GU toxicity, 7%
other toxicities grade III + IV
Wang et al.
[160]
2011 Prospective 26 Stage III/IV
NSCLC
Median 70 Gy Grade IV leukopenia 4%, grade IV
thrombopenia 8%, grade III esophagitis 4%,
grade III pneumonitis 4%
Zhang et al.
[161]
2009 Phase I 24 NSCLC 54-60 Gy 4% grade III nausea
Chen et al.
[162]
2007 Phase I 23 HNSCC Up to 72 Gy 13% grade III dermatitis, 57% grade III + IV
mucositis, 39% grade III + IV dysphagia, 17%
grade III + IV diarrhea, 30% grade III + IV
neutropenia, 9% grade III + IV anemia, 4%
grade IV tumour hemorrhage, 4% grade III GI
bleeding
Maurel et al.
[163]
2006 Phase I 18 Pancreatic
cancer
45 Gy No DLT, 11% grade III + IV neutropenia, 6%
anemia grade III
Czito et al.
[164]
2006 Phase I 16 Pancreatic +
rectal cancer
50.4 Gy (1.8 Gy) +
capecitabine
31% grade III + IV diarrhea
Center et al.
[165]
2010 Phase I 16 NSCLC 70 Gy 3D-CT + docetaxel 27% grade III + IV hematotoxicity, 27% grade
III + IV esophagitis, 20% grade III + IV
pulmonary toxicity
Schwer et al.
[166]
2008 Phase I 15 Malignant
glioma
SRS 18-36 Gy No DLT, no grade > II
Olsen et al.
[167]
2009 Phase I 12 Pancreatic
cancer
50.4 Gy (1.8 Gy) 45% grade III nausea
erlotinib Brown et al.
[168]
2008 Phase I/II 79 GBM 60 Gy + TMZ 18% grade III/IV rash, 16% grade III/IV fatigue,
24% grade III/IV thrombopenia, 4% grade III
nausea, 8% grade III diarrhea, 28% grade III/IV
leukopenia, 3% grade III anorexia, 18% grade
III/IV neutropenia, 6% grade III anemia, 14%
grade III lymphopenia, 1% grade V infection
without neutropenia, 5% grade III infection
without neutropenia, 6% grade III/IV dyspnea,
1% grade III/IV keratitis, 1% grade V
pneumonitis, 6% grade III/IV pneumonitis
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Prados et al.
[169]
2009 Phase II 65 GBM 59.4 Gy/60 Gy + TMZ 43% grade III lymphopenia, 3% grade IV
neutropenia, 2% grade IV thrombopenia, 8%
grade III/IV fatigue, 2% grade III diarrhea, 6%
grade III rash
Herchenhorn
et al. [170]
2010 Phase I/II 37 LA-HNSCC 70 Gy + Cis No DLT
Choong et al.
[171]
2008 Phase I 34 NSCLC Stage III 66 Gy (2 Gy), Arm A:
Erlotinib + Cis/Eto, Arm B:
Induction Carbo/Tax, Carbo/
Tax + Erlotinib
41% grade III + IV WBC, 32% grade III + IV
neutropenia, 21% grade III + IV thrombopenia,
26% grade III + IV esophagitis, 3% grade III +
IV vomiting, 6% grade III + IV diarrhea, 3%
grade III/IV pneumonitis/ototoxicity
Peereboom
et al. [172]
2010 Phase II 27 GBM 60 Gy + TMZ 7% grade V febrile neutropenia, 4% grade V
sepsis without neutropenia, 4% grade V PCP,
a pt grade III neutropenia, 15% grade III
neutropenia, 30% grade III + IV thrombopenia,
56% pts grade III lymphopenia, 15% grade III
+ IV anemia, 7% grade III fatigue
Chang et al.
[173]
2011 Retrospective 25 NSCLC 40-50 Gy 4% grade III rash, 4% grade III diarrhea/
esophagitis/anemia, 8% grade III neutropenia/
thrombopenia, 8% grade V pneumonitis, 4%
grade III pneumonitis
Li et al. [174] 2010 Phase II 24 LA esophageal
cancer
60 Gy + Carbo/Tax 17% ≥ grade III leukopenia, 8% thrombopenia
≥ grade III
Broniscer et
al. [175]
2009 Phase I 23 GBM 54-59.4 Gy 39% grade III + IV lymphopenia, 4% grade III
rash, 4% grade III diarrhea
Robertson et
al. [176]
2009 Phase I 22 Pancreatic
cancer
Gem weekly, 30-38 Gy 5% grade III vomiting/fatigue/nausea, 5%
grade III vomiting/diarrhea/nausea, 9% grade
IV fatigue
Duffy et al.
[177]
2008 Phase I 20 Pancreatic
cancer
50.4 Gy + Gem 100% grade III lymphopenia, 25% grade III
thrombopenia, 30% grade III neutropenia, 5%
grade IV neutropenia, 10% grade III anemia,
5% grade III fatigue, 15% grade III diarrhea,
10% grade III rash
Krishnan et
al. [178]
2006 Phase I 20 GBM 60 Gy 15% grade III stomatitis, 5% grade III fatigue/
diarrhea
Iannitti et al.
[179]
2005 Phase I 17 LA Pancreatic
cancer
50.4 Gy + Tax/Gem 6% grade III nausea/fatigue/rash/small bowel
stricture/thrombopenia (each), 18% grade III
dehydration/thrombosis, 12% grade III
diarrhea/hypersensitivity, 6% grade IV
neutropenia
Nogueira-
Rodrigues et
al. [180]
2008 Phase I 15 LA cervical
cancer
45 Gy + brachyTx + CisPt 7% grade IV hepatotoxicity, 7% grade III
dermatitis, 20% III diarrhea, 13% grade III rash
Arias de la
Vega et al.
[181]
2011 Phase I 13 LA-HNSCC 63 Gy + Cis adjuvant Grade III/IV: Mucositis 54%, Asthenia 15%, skin
23%, diarrhea 15%.
Lind et al.
[182]
2009 Phase I 11 NSCLC, brain
metastases
WBRT (30 Gy) 9% grade III rash/fatigue
Dobelbower
et al. [183]
2006 Phase I 11 Esophageal
cancer
50.4 Gy + 5-FU 36% pts grade III + IV leukopenia, 9% grade III
anemia, 9% grade III thrombopenia, 18%
grade III + IV neutropenia, 27% grade III
dehydration, 9% grade III nausea, 9% grade
III/9% grade IV esophagitis
Silvano et al.
[82]
2008 Case report 1 NSCLC 2 × 8 Gy Death caused by fatal diarrhea
Huang et al.
[184]
2008 Case study 1 NSCLC WBRT 37.5 Gy Death caused by exacerbated radiodermatitis
and subdural hemorrhage
mTOR
inhibitors
(Sirolimus)
Sarkaria et al.
[185]
2007 Phase I 7 NSCLC 60 Gy + CisPt weekly 14% grade III dysphagia, esophagitis, febrile
neutropenia, pneumonia
Bourgier et
al. [186]
2011 Case reports 3 Breast/prostate/
ovary cancer
45 Gy/70 Gy, later Gastrointestinal radiation recall syndrome with
everolimus/temsirolimus
N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, HCC-hepatocellular carcinoma, RCC-renal cell cancer, GBM-glioblastoma multiforme,
DVT-deep vein thrombosis, Fx-fractions, SRS-stereotactic radiosurgery, DLT-dose limiting toxicity, LA-locally advanced, Gem-gemcitabine, Tax-Taxol (paclitaxel), Tx-
therapy, TMZ-temozolomide, PCP-Pneumocystis pneumonia, Cis-cisplatin, Eto-etoposide,
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study, only the known side effects of thalidomide
occurred in the usual frequency. Hints to a possible
interaction with radiotherapy have not been reported.
Nearly half of the patients discontinued the study in the
thalidomide arm due to side effects. The major limiting
side effect was somnolence [93].
In malignant glioma, thalidomide was used in combi-
nation with radiotherapy or radiotherapy plus temozolo-
mide in primary or recurrent settings [94].
Intratumoural bleeding and thromboembolic complica-
tions have been reported. However, the rate of compli-
cations was not higher than the reported rates for
thalidomide alone [95-97].
Other studies, combining radiotherapy of soft tissue/
bone metastasis as well as pelvic tumours with thalido-
mide simultaneously or sequentially revealed no evidence
for increased risks of acute or late side effects [99].
However, a single study using radiotherapy (66 Gy in
33 fx) combined with vinorelbine and thalidomide in
NSCLC stage III was abrogated after 10 patients due to
side effects (thromboembolic, 1 bradycardia II°) [100].
As in this study only known side effects of thalidomide
occurred, it still remains unclear whether radiation
including the lung or the heart leads to increased side
effects when combined with thalidomide.
Altogether the combination of thalidomide with
simultaneous or sequential RT does not seem to be cri-
tical. Only in cases when large volumes of the heart or
the lung are exposed, a certain level of cautiousness
should be advised.
Lenalidomide
Lenalidomide is a derivative of thalidomide. Thus, the
anti-angiogenic effect and the adverse effects are to a
large extent similar to thalidomide. However, it largely
lacks the sedative side effect, making it better tolerable
for patients. Leukopenia and thrombocytopenia have
also been reported.
In Europe and the US it is only approved in combina-
tion with dexamethasone for the treatment of multiple
myeloma as 2nd line therapy. There is only very limited
data regarding the combination of lenalidomide and
radiotherapy. A single phase I trial [101] in glioblastoma
used lenalidomide with RT (60 Gy, 30 fx). Thromboem-
bolic events, pneumonitis and elevation of transaminases
have been reported. The maximal tolerable dose was
reported to be 15 mg/m
2, corresponding to the respec-
tive dose for monotherapy. Being chemically similar to
thalidomide and having a similar profile of side effects,
one can indirectly assume a similar pattern of interac-
tion with radiation.
Imatinib
Imatinib is a tyrosine-kinase inhibitor (TKI) of bcr-abl,
PDGFR alpha/beta and c-kit. The first successful clinical
application of imatinib was in chronic myeloid leukae-
mia as the bcr-abl-fusion gene plays a crucial role in
this disease. As GIS-tumours display a high number of
c-kit-mutations, they are currently also treated with
imatinib. Imatinib alone is usually well tolerated. Known
adverse effects are diarrhea, nausea, vomiting, erythema,
edema or the increase of transaminases; leukopenia or
thrombopenia usually occur only in leukemic diseases.
Grade III-IV toxicity is reported in fewer than 10% of
the patients.
Several in vitro experiments showed a putative radio-
sensitizing effect of imatinib [102]. Additionally it has
been shown, that the proliferation of fibroblasts can be
slowed down in vitro by imatinib [103]. This leads to
Table 4 Studies on thalidomide and derivatives.
Substance Author
(s)
Year Study
type
N tumour RT dose/ChTx/
technique
Toxicity
Thalidomide Knisely et
al. [93]
2008 Phase
III
332 (90
thalidomide)
Brain
metastases
37,5 Gy (2,5 Gy) 53% interruptions because of side-effects
Chang et
al. [187]
2004 Phase
II
67 GBM 60 Gy (2 Gy),
TMZ
concomitant
10% grade III + IV neutropenia, 1% grade V; 16% grade III +
IV thrombopenia, 9% grade III + IV rash, 1% grade III
constipation, 9% grade III fatigue
Atkins et
al. [188]
2008 Phase
II
39 CNS
metastases
(melanoma)
30 Gy (3 Gy)
WBRT + TMZ
concomitant
10% grade III + IV + V thrombosis, 5% grade III + IV + V
myelosuppression, 8% grade III + IV + V cardiac events
Ch’ang et
al. [189]
2011 Phase
II
24 HCC 50 Gy (2 Gy) 54% rash, 38% somnolence, 33% constipation
Turner et
al. [97]
2007 Phase
II
13 Brainstem
glioma +
GBM
55.8 Gy (1.8 Gy) 8% grade IV DVT, ≥ 15% grade III leukopenia/
motoneuropathy/constipation
Lenalidomide Drappatz
et al.
[101]
2009 Pilot
study
23 GBM 60 Gy (2 Gy) 4% grade IV pneumonitis/hypoxia, 9% grade III nausea, 4%
grade IV pulmonary embolism, 4% grade III pneumonia
N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, LA-HNSCC-locally advanced head-and-neck cancer, GBM-glioblastoma multiforme,
DVT-deep vein thrombosis
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nib with regard to radiation-induced fibrosis. Three in
vivo experiments support this hypothesis [104-106].
Regarding the clinical use of radiotherapy and imatinib
only limited data is available. Imatinib has been used in
recurrent glioma after radiotherapy (one 112-patient-
trial with imatinib alone after radiotherapy and three
30-40-patient trials in combination with hydroxyurea).
Unexpected adverse effects pointing to an increased
toxic profile for the sequential use have not been
reported [107-110]. In another trial, 27 patients have
been treated with imatinib after radiotherapy in prostate
cancer without unexpected side effects [111].
There is only one clinical phase I study regarding the
simultaneous application of imatinib to radiotherapy
(55.8 Gy in 21 fx) in children with brainstem-tumours.
Retrospectively compared to a similar collective, subcli-
nical bleeding seemed increased, but no other unex-
pected toxicities have been reported [112]. Additionally,
there are two case reports for the combinational
approach [113,114]. Again, in both cases no unexpected
side effects have been reported.
Altogether, sequential application of imatinib with
radiotherapy might not bear an increased risk for
adverse effects. For the simultaneous application the
limited amount of data does not allow a valid judgement
about potentially increased side effects.
Discussion
Radiotherapy combined with molecular targeted agents
may be associated with unforeseen yet specific toxicities.
Based on putative interactions of radiotherapy and the
given agent with the targeted signalling cascade, any
interactions may not only interfere with any anti-tumour
efficacy but may also increase side effects. On the other
hand, also radio-protectivee f f e c t sf o rt h et u m o u ra r e
possible if new combined treatment schedules are used.
Examples are cetuximab in multimodal radio-che-
motherapy regimens for rectal cancer [115-119] or ery-
thropoietin, which was thought to increase the
haemoglobin level in head-and-neck cancer patients, but
decreased survival most likely due to EPO-receptors on
the cancer cells which were not known as a proliferative
factor for tumours before [120,121].
However, there are still clinical situations where
patients may benefit from the application of a targeted
drug in combination with radiotherapy outside approved
treatment schedules or clinical trials. The best example
is a palliative systemic treatment for disseminated
metastases and at the same time an indication for pallia-
tive or symptomatic radiotherapy of a single region. In
this case, interruption of the systemic treatment may
lead to systemic progression under radiotherapy. The
present work aims to provide a helpful tool for clinical
treatment decisions in such situations.
At present, only limited data is available on the inter-
actions of targeted agents and radiotherapy. Data on
toxicity are mostly derived from small case series, retro-
spective analyses or at best cohort and few randomized
studies. For most substances, mild complications are
reported-however, rarely exceptional fatal complications
have been documented.
Overall, for any of the drugs mentioned here indica-
tions for a combination with radiotherapy have to be
made cautiously (is a sequential treatment possible?).
Furthermore, patients have to be questioned very speci-
fically regarding the intake of targeted drugs. Frequently
patients have been advised that these drugs are not
“classical cytostatic drugs”.T h u sp a t i e n t so f t e nd on o t
self-report intake of targeted drugs when counselled for
radiotherapy.
Simultaneous applications of targeted drugs during
radiotherapy in non-established schedules should be an
exception and reserved for those patients where the sys-
temic tumour situation mandates rapid treatment.
Whenever possible, large volume radiotherapy plus tar-
geted drugs should be avoided. These remarks are espe-
cially important for hypo-fractionated regimens where
high toxicities have been observed (in part with fatal
consequences).
In conclusion, molecular targeted agents should only
very cautiously in combination with radiotherapy. A
meticulous and careful balancing of benefits and risks of
increased toxicity is advised.
Abbreviation
CNS: central nervous system; CT: chemotherapy; DFS: disease-free survival;
EBRT: external beam radiotherapy; EGFRi: epidermal growth factor receptor
inhibitor; IGRT: image-guided radiotherapy; KPS: Karnofsky Performance
Status; mo: months; mPFS: median progression-free survival; MST: median
survival time; MTD: maximum tolerated dose; mTOR: mammalian target of
rapamycin.; mTTP: median time to progression; NTD: normalized total dose;
OS: overall survival; PFS-6/-12: progression-free survival rate at 6/12 months;
pt(s): patient(s); PTEN: phosphatase and tensin homolog deleted on
Chromosome 10; QOL: quality of life; RCHT: radio-chemotherapy; RT:
radiotherapy; VEGF-R: vascular endothelial growth factor receptor; WBRT:
whole brain radiotherapy; wk: week.
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